Literature DB >> 22000668

The antibiotic treatment of PPROM study: systemic maternal and fetal markers and perinatal outcomes.

Brian M Mercer1, Dennis T Crouse, Robert L Goldenberg, Menachem Miodovnik, Delicia C Mapp, Paul J Meis, Mitchell P Dombrowski.   

Abstract

OBJECTIVE: We sought to correlate maternal and cord blood cytokine and intercellular adhesion molecule-1 levels with antibiotic exposure and perinatal outcomes after conservatively managed preterm premature rupture of the membranes. STUDY
DESIGN: Conservatively managed women with preterm premature rupture of the membranes at 24-32 weeks had blood sampling at randomization (n = 222) and delivery (n = 121). Plasma from these, and umbilical cord blood (n = 196), was stored at -70°C. Interleukin (IL)-6, IL-10, granulocyte colony-stimulating factor (G-CSF), tumor necrosis factor-α, and intercellular adhesion molecule-1 levels were assessed for associations with antibiotic treatment, latency, amnionitis, neonatal sepsis, pneumonia, and composite neonatal morbidity.
RESULTS: Cord blood IL-6 and G-CSF were higher than maternal levels. Antibiotic treatment lowered only maternal G-CSF (P = .01). Elevated maternal cytokine levels were associated with delivery within 7 days and with development of chorioamnionitis. All umbilical cord blood markers were increased with amnionitis (P ≤ .01 for each). No maternal marker was associated with neonatal morbidities. Cord G-CSF and IL-6 were increased with neonatal sepsis within 72 hours of birth (P = .004 for both), and with composite neonatal morbidity (P = .001 and .002, respectively). Maternal and umbilical cord cytokine levels demonstrated low predictive values for perinatal outcomes.
CONCLUSION: Umbilical cord blood cytokine values are higher than maternal levels, suggesting significant fetal/placental contribution. Maternal and umbilical cord cytokine levels are not adequately predictive to be used clinically.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000668      PMCID: PMC3262066          DOI: 10.1016/j.ajog.2011.08.028

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

1.  Interleukin-6 and interleukin-1 receptor antagonist in amniotic fluid and cord blood in patients with pre-term, premature rupture of the membranes.

Authors:  H Fukuda; H Masuzaki; T Ishimaru
Journal:  Int J Gynaecol Obstet       Date:  2002-05       Impact factor: 3.561

2.  Clinical application of maternal serum cytokine determination in premature rupture of membranes--interleukin-6, an early predictor of neonatal infection?

Authors:  K A Pfeiffer; J Reinsberg; A Rahmun; J Schmolling; D Krebs
Journal:  Acta Obstet Gynecol Scand       Date:  1999-10       Impact factor: 3.636

3.  Detection of interleukin-6 in maternal plasma predicts neonatal and infectious complications in preterm premature rupture of membranes.

Authors:  D F Lewis; P S Barrilleaux; Y Wang; C D Adair; J Baier; T Kruger
Journal:  Am J Perinatol       Date:  2001-11       Impact factor: 1.862

Review 4.  Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes.

Authors:  R Romero; M Sirtori; E Oyarzun; C Avila; M Mazor; R Callahan; V Sabo; A P Athanassiadis; J C Hobbins
Journal:  Am J Obstet Gynecol       Date:  1989-09       Impact factor: 8.661

Review 5.  Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection.

Authors:  R Gomez; R Romero; S S Edwin; C David
Journal:  Infect Dis Clin North Am       Date:  1997-03       Impact factor: 5.982

6.  Umbilical cord plasma interleukin-6 concentrations in preterm infants and risk of neonatal morbidity.

Authors:  Alice R Goepfert; William W Andrews; Waldemar Carlo; Patrick S Ramsey; Suzanne P Cliver; Robert L Goldenberg; John C Hauth
Journal:  Am J Obstet Gynecol       Date:  2004-10       Impact factor: 8.661

7.  Predictive value of serum interleukin-6 and -8 levels in preterm labor or rupture of the membranes.

Authors:  G von Minckwitz; E M Grischke; S Schwab; S Hettinger; S Loibl; M Aulmann; M Kaufmann
Journal:  Acta Obstet Gynecol Scand       Date:  2000-08       Impact factor: 3.636

8.  Mid-pregnancy circulating cytokine levels, histologic chorioamnionitis and spontaneous preterm birth.

Authors:  Julia Warner Gargano; Claudia Holzman; Patricia Senagore; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Mohammad H Rahbar; Hwan Chung
Journal:  J Reprod Immunol       Date:  2008-09-23       Impact factor: 4.054

Review 9.  Preterm premature rupture of the membranes.

Authors:  Brian M Mercer
Journal:  Obstet Gynecol       Date:  2003-01       Impact factor: 7.661

Review 10.  Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology.

Authors:  R Gomez; F Ghezzi; R Romero; H Muñoz; J E Tolosa; I Rojas
Journal:  Clin Perinatol       Date:  1995-06       Impact factor: 3.430

View more
  11 in total

Review 1.  Time for a neonatal-specific consensus definition for sepsis.

Authors:  James L Wynn; Hector R Wong; Thomas P Shanley; Matthew J Bizzarro; Lisa Saiman; Richard A Polin
Journal:  Pediatr Crit Care Med       Date:  2014-07       Impact factor: 3.624

2.  Identification of a gene in Mycoplasma hominis associated with preterm birth and microbial burden in intraamniotic infection.

Authors:  Matthew Josiah Allen-Daniels; Myrna G Serrano; Lindsey P Pflugner; Jennifer M Fettweis; Melissa A Prestosa; Vishal N Koparde; J Paul Brooks; Jerome F Strauss; Roberto Romero; Tinnakorn Chaiworapongsa; David A Eschenbach; Gregory A Buck; Kimberly K Jefferson
Journal:  Am J Obstet Gynecol       Date:  2015-01-28       Impact factor: 8.661

Review 3.  Preterm prelabor rupture of the membranes: A disease of the fetal membranes.

Authors:  Ramkumar Menon; Lauren S Richardson
Journal:  Semin Perinatol       Date:  2017-08-12       Impact factor: 3.300

4.  Impact of duration of rupture of membranes on outcomes of premature infants.

Authors:  M W Walker; A H Picklesimer; R H Clark; A R Spitzer; T J Garite
Journal:  J Perinatol       Date:  2014-04-24       Impact factor: 2.521

5.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

6.  Antibiotic Therapy for Premature Rupture of Membranes and Preterm Labor and Effect on Fetal Outcome.

Authors:  B Seelbach-Goebel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

7.  A new antibiotic regimen treats and prevents intra-amniotic inflammation/infection in patients with preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-12-02

8.  Human β-defensin-1: A natural antimicrobial peptide present in amniotic fluid that is increased in spontaneous preterm labor with intra-amniotic infection.

Authors:  Aneesha Varrey; Roberto Romero; Bogdan Panaitescu; Derek Miller; Tinnakorn Chaiworapongsa; Manasi Patwardhan; Jonathan Faro; Percy Pacora; Sonia S Hassan; Chaur-Dong Hsu; Nardhy Gomez-Lopez
Journal:  Am J Reprod Immunol       Date:  2018-08-12       Impact factor: 3.886

9.  Cesarean section and pregnancy outcomes of preterm premature rupture of membranes under different fertility policies in China.

Authors:  Haili Jiang; Chang Lu; Jianxin Zhou; Weiyuan Zhang
Journal:  Transl Pediatr       Date:  2021-04

10.  Proteomic Analysis of Early Mid-Trimester Amniotic Fluid Does Not Predict Spontaneous Preterm Delivery.

Authors:  Maria Hallingström; Juraj Lenco; Marie Vajrychova; Marek Link; Vojtech Tambor; Victor Liman; Maria Bullarbo; Staffan Nilsson; Panagiotis Tsiartas; Teresa Cobo; Marian Kacerovsky; Bo Jacobsson
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.